Galaxy Gas Litigation Is Maturing. The Inhalant Regulatory Vacuum Isn't Closing.
The FDA expanded its warning. Lawsuits are advancing. The structural gap in U.S. inhalant regulation is still wide open.
Galaxy Gas Litigation Is Maturing. The Inhalant Regulatory Vacuum Isn’t Closing.
The Galaxy Gas story has been moving along two tracks for the past year. On the regulatory track: the FDA issued an initial warning in March 2025 urging consumers not to recreationally inhale nitrous oxide products of any flavor or canister size, and expanded the advisory in June 2025 after reports of additional adverse events. Galaxy Gas paused direct sales from its website. On the litigation track: class action and wrongful death cases continue to multiply, and a judicial conference on the multidistrict litigation took place January 9, 2026.
What hasn’t closed — and the FDA can’t close alone — is the structural regulatory gap. Recreational nitrous oxide products in the United States are sold without FDA certification, mandatory purity testing, or canister size limits. The food-grade designation that historically governed nitrous oxide cartridges intended for whipped cream production is the closest thing to a federal floor on what’s sold; it was not designed for the recreational use case and does not address consumer-facing labeling, dosing limits, or contraindications.
The dominant injury pattern in the medical literature has been B12 deficiency leading to subacute combined degeneration of the spinal cord — a neurological injury that, when caught early, partially reverses but does not always fully heal. The pediatric and adolescent literature has been catching up with the adult presentation. Phoenix-area emergency departments have not been a national hotspot for these presentations in 2025–2026, but national poison control center data suggests they are increasing.
For families: the question is less whether the FDA’s warning will land — it has — and more whether labeling, age-of-purchase restrictions, or canister-size caps will follow. None of those tools are currently in active federal rulemaking. Most regulation here, as with kratom and at-home ketamine, will probably be done by state legislatures and the civil courts before a federal floor materializes.
Sources Cited
- 01.B
- 02.B
- 03.B
Filed Under
policyharm-reductionsocial-cultural
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Naloxone Still Reverses Fentanyl. It Doesn't Touch What's Being Cut Into It Now.
Nitazenes (up to 40x fentanyl's strength) have been confirmed in 48 of 50 states, and a veterinary sedative called medetomidine is spreading through the fentanyl supply. Naloxone doesn't fully reverse either one. Here's what actually changes for harm reduction.
Harm ReductionXylazine Was the Adulterant Everyone Learned to Test For. Medetomidine Is 300 Times Stronger, and the Government Just Defunded the Strips That Catch It
Medetomidine, a veterinary sedative up to 300 times more potent than xylazine, is displacing tranq in the fentanyl supply. Here's the science, the scheduling fight, and why test strips matter more than ever.
Harm ReductionSubstance Spotlight: Inhalants Are the Overdose Crisis Nobody Is Watching, and It's Getting Younger
2024 NSDUH data shows 3.2 million Americans used inhalants in the past year, with teen rates far outpacing adults. A wave of 2026 state legislation targets flavored nitrous oxide products like Galaxy Gas.